FKK has served on scientific advisory panels and/or been part of speakers bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, Lupin, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Pharmacosmos, Sanofi, ShouTi, Zealand Pharma and Zucara
Figure 1: Transversal (A) and longitudinal (B) view of the blood-brain barrier
doi: 10.1006/bioo.1995.1016
Peptide-targeted radionuclides: Peptide receptor radionuclide therapy Peptide receptor radionuclide therapy (PRRT) involves the combination of a tumor-homing peptide with a radionuclide or radioactive isotope as the therapeutic substance
While promising, the technology is still developing, and its effectiveness can be inconsistent
Advances in Lipid Nanocarrier Design and Encapsulation Efficiency Modern liposomal systems have moved beyond traditional thin-film hydration methods toward microfluidic and high-pressure homogenization techniques, which enable more precise control of particle size, encapsulation efficiency, and scalability
